Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Mississippi Healthcare Reporter.
July 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 | 31 |
August 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | ||||
| 4 | 5 | 6 | 7 | 8 | 9 | 10 |
| 11 | 12 | 13 | 14 | 15 | 16 | 17 |
| 18 | 19 | 20 | 21 | 22 | 23 | 24 |
| 25 | 26 | 27 | 28 | 29 | 30 | 31 |
September 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 |
| 8 | 9 | 10 | 11 | 12 | 13 | 14 |
| 15 | 16 | 17 | 18 | 19 | 20 | 21 |
| 22 | 23 | 24 | 25 | 26 | 27 | 28 |
| 29 | 30 |
Press releases published on September 1, 2025
Bone Marrow Failure Market Growth Accelerates with Advances in Cell and Gene Therapy | DelveInsight
GlobeNewswire
·
September 1, 2025
New York, USA, Sept. 01, 2025 (GLOBE NEWSWIRE) -- Bone Marrow Failure Market Growth Accelerates with Advances in Cell and Gene Therapy | DelveInsight The bone marrow failure market is witnessing steady growth driven by the increasing prevalence of aplastic …
Healthcare Champions Launch Public Education Campaign to Address New Mexico’s Medical Access Crisis
GlobeNewswire
·
September 1, 2025
Santa Fe, NM, Sept. 01, 2025 (GLOBE NEWSWIRE) -- A new public education campaign has been launched by Patient-Led NM, founded by the New Mexico Medical Society, New Mexico Hospital Association, Sacramento Mountains Foundation, and the Greater Albuquerque …
KFSHRC to Participate as Strategic Partner in C3 Davos of Healthcare New York Summit
GlobeNewswire
·
September 1, 2025
NEW YORK, Sept. 01, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital …
Oculis to Present Clinical Trial Results in Diabetic Macular Edema and Acute Optic Neuritis at Ophthalmology Conferences
GlobeNewswire
·
September 1, 2025
Phase 2 ACUITY trial results for Privosegtor (OCS-05) in acute optic neuritis to be presented in EURETINA late-breaking session Expanded data analysis from Phase 3 Stage 1 DIAMOND program for OCS-01 eye drops in diabetic macular edema (DME) to be presented …
Boehringer’s HERNEXEOS® approved in China as first oral targeted therapy for previously treated patients with HER2-mutant advanced NSCLC
GlobeNewswire
·
September 1, 2025
This press release is not intended for UK and US media. HERNEXEOS® (zongertinib tablets) has been approved based on an objective response rate of 71% (N=75), as demonstrated in the Beamion-LUNG 1 clinical trial1 Zongertinib recently received Breakthrough …